You are here: Industry Insights > Roche

News List

Sanofi gains OTC rights to Roche’s Tamiflu in US pharmaceutical-technology
July 24, 2019
Sanofi has entered an agreement to obtain the exclusive over-the-counter (OTC) rights for Roche’s Tamiflu medicine.
Pistoia Alliance, backed by Roche, AZ and Bayer, to Introduce FAIR Project contractpharma
July 17, 2019
Includes a toolkit to help companies implement the FAIR guiding principles.
ImaginAb teams up with Roche for multiple cancer clinical trials biospectrumasia
July 10, 2019
Roche will use ImaginAb's novel minibody CD8 T cell imaging agent in immuno-oncology clinical trials for multiple types of cancers
AstraZeneca’s Imfinzi tees up small cell lung cancer fight with Roche fiercepharma
July 04, 2019
After Imfinzi's key non-small cell lung cancer trial failure last year, AstraZeneca has some good news to report in lung cancer. But it's from the much smaller field of small cell lung cancer where Roche’s Tecentriq is a step ahead.
Alexion nabs potential $1B indication for Soliris, but it'll have to take on Roche's cheaper Rituxan fiercepharma
July 04, 2019
In an effort to protect its blockbuster Soliris, Alexion has employed a double strategy of nabbing additional approvals and positioning follow-up drug Ultomiris to switch over sales. Alexion added another indication this week that could rake in $1 billion
Pharma shells out $3B to doctors and hospitals—with Roche, Sanofi leading: CMS fiercepharma
July 04, 2019
As massive marketing crackdowns and kickback lawsuits circulate through U.S. courtrooms, scrutiny on pharma's financial ties to healthcare providers has never been higher.
FDA lifts hold on AbbVie, Roche's Venclexta in myeloma after drugmakers pledge risk remedies fiercepharma
June 28, 2019
After a spate of trial deaths forced AbbVie and Roche to halt trial enrollment for oncology med Venclexta in multiple myeloma, the future seemed dim for the drug’s expansion hopes in the disease. But now, after taking steps to increase safety, the drugmak
After Roche, BMS surprises, what does AbbVie need to do to win FTC clearance for Allergan buy? fiercepharma
June 28, 2019
But now, as Yee put it, the Otezla roadblock “is a potential read-through that the FTC is being tougher on regulating competition,” and it could mean future dealmakers may need to be more careful.
Roche wins Japan approval for personalised cancer drug Rozlytrek expresspharma
June 21, 2019
Swiss drugmaker Roche’s push into personalised cancer medicines hit a milestone with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified via genetic profiling.
Japan first to approve Roche’s tumour-agnostic medicine Rozlytrek pharmaceutical-technology
June 20, 2019
Japan approves Roche’s personalised medicine Rozlytrek. Credit: © 2015 F. Hoffmann-La Roche.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page